News Related to Tisagenlecleucel

Related coverage linked through entity extraction aliases.

Tandem 2026 highlights CAR-T, transplant and supportive-care advances

Apr 06, 2026

The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.

Citius Oncology Reports LYMPHIR Revenue and Positive Phase 1 CAR-T Combination Data

Mar 04, 2026

Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.